The intro rate is published next to the price it becomes
Most sellers here that run a first-month rate advertise it and let the ongoing figure appear later. This card does the opposite: the ongoing rate is the large number, the first order sits directly beneath it with a stated saving, and the plan grid repeats both as a pair — first month, then the rate after.
Fourteen of the ninety-five sellers here carry a recorded introductory rate. Printing the ongoing figure beside it, in the same size, is the version of that disclosure a reader can act on, and it is why this row scores for price stability while most introductory-rate rows do not.
Our record stores the ongoing rate as the price and the first order as an introductory offer, which keeps the opening number out of any calculation of what a year costs.
Four commitment lengths, both drugs, in a grid
Beneath the card sits a grid: monthly, three months, six months, twelve months, each with its own per-month figure, for each of the two drugs. Nothing is behind a quiz and nothing requires an email.
The spread across the ladder is wide, and the lowest figure on either drug requires a twelve-month commitment. The grid does not print the prepaid totals, which is the one thing it is missing — a reader has to multiply to see what leaves the account.
The card also states the terms plainly in one line: no membership fees, same price at every dose, medication and injection supplies included. Forty-one of the ninety-five sellers here charge no membership.
The cancellation language is unusually complete. It says you can cancel from the portal with no fees and no long-term contracts, and then states the limit — cancelling will not recall an order already sent to the pharmacy — with an email address for orders still pending. A promise with its exception attached is worth more than a promise.
The FDA letter, and what the pages say now
The agency reviewed this site in August 2025 and wrote in September. It quoted two passages: one describing compounded GLP-1 medications as containing the same active ingredient as the branded medications, and one describing a semaglutide oral dissolving tablet as delivering the same active ingredient found in the leading brand-name products without injections. The finding is that such claims imply the products are the same as an approved product when they are not.
Fourteen of the ninety-five sellers here carry a recorded FDA warning letter. It is a disclosure and not a finding of guilt, and this comparison does not treat one as a reason to score a company down. The number, the date and a link to the agency's own text are on this row.
We searched the visible text of both product pages on 6 September 2026 for the phrase both quoted passages turn on. It returns zero occurrences on both. That is what two pages said on one day. It is not a statement that the matter is resolved, and nothing published anywhere tells us whether it is.
One related absence is worth flagging. The oral dissolving tablet named in the second quoted passage does not appear as a priced product on either page we read. Whether that lane was withdrawn, renamed or simply moved, the site does not say.
The fifty-state sentence is about somebody else
Both product pages carry a sentence saying that all medications prescribed through this service are compounded at pharmacies licensed in all fifty states and held to the highest accreditation standards.
Read the subject of that sentence. It is a claim about where a pharmacy holds licences, not a statement that this seller will accept a patient in every state. Those are different questions and only one of them is answered.
Our record therefore carries no state list, with the census attached: both product pages and the HIPAA privacy statement were read and none names a served state or an exclusion. Fifty-eight of the ninety-five sellers here publish no service area at all. A sentence containing the words all fifty states is not the same as a coverage list, and turning it into one would be this comparison inventing a fact.
Categories where names should be
The pharmacies are state-licensed, certified, accredited and licensed in all fifty states. They are never named. Sixty-nine of the ninety-five sellers here name no compounding pharmacy at all.
The clinicians are licensed medical providers who review your health profile and build a plan. None is named. Fifty-one of the ninety-five sellers here name nobody who prescribes.
The company itself is named cleanly, in the first sentence of its HIPAA privacy statement and in the copyright line, under a corporate name that differs from the brand — which is ordinary and which is also exactly how the FDA letter is addressed.
What the pages do say about quality is specific: each batch third-party tested in FDA- and DEA-registered labs. That is a checkable-sounding claim with no name attached to check it against, which is the shape of nearly every quality claim in this field.
Elevated Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $296/moThe ONGOING monthly rate, printed beside the first-order rate rather than behind it: "Compounded Semaglutide, Personalized for Your Weight Loss / $296 / for a 1-month supply* / First order for $196 / Risk-Free for 30 Days" and, in the plan grid, "Monthly Plan / $196 first month / $296/mo after". | September 2026source |
| Semaglutide (compounded) | $242/moFrom the published plan grid: "3-Month Plan / $242 per month". | September 2026source |
| Semaglutide (compounded) | $229/moFrom the published plan grid: "6-Month Plan / $229 per month". | September 2026source |
| Semaglutide (compounded) | $187/moFrom the published plan grid: "12-Month Plan / $187 per month", and repeated as the site-wide "Compounded Semaglutide / Starting at $187/mo". | September 2026source |
| Tirzepatide (compounded) | $359/moThe ongoing monthly rate: "$359 / for a 1-month supply* / First order for $259", and in the plan grid "Monthly Plan / $259 first month / $359/mo regular". | September 2026source |
| Tirzepatide (compounded) | $304/moFrom the published plan grid: "3-Month Plan / $304 per month". | September 2026source |
| Tirzepatide (compounded) | $281/moFrom the published plan grid: "6-Month Plan / $281 per month". | September 2026source |
| Tirzepatide (compounded) | $235/moFrom the published plan grid: "12-Month Plan / $235 per month". | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 95 providers reviewed here are paid partners today; the other 91 are not. See how this works.
See Elevated Health's current price →Good fit if
- Readers who want the first-order rate and the ongoing rate printed side by side, in the same size, on the same card.
- Buyers who want every commitment length priced in a grid before an intake.
- People who want a cancellation promise with its exception stated rather than a bare guarantee.
- Anyone who wants a stated absence of membership fees and a stated flat price across doses.
Look elsewhere if
- Readers for whom an FDA warning letter about product claims is a filter, even where the cited wording no longer appears.
- Buyers who want the compounding pharmacy or an individual prescriber named. Neither appears anywhere.
- Anyone who reads the fifty-state sentence as a coverage list. It describes where pharmacies hold licences, not where this service operates.
- People unwilling to commit for a year. The lowest published figure on either drug requires twelve months.
- Readers wanting the oral dissolving tablet the FDA letter names. It is not a priced product on either page we read.
How this review was verified
- Re-read both product pages and the HIPAA privacy statement on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller.
- Recorded eight price rows — four commitment lengths for each drug — plus two introductory offers, rather than storing one headline figure per drug, and stored the ongoing rate as the price so no calculation of a year starts from the first-order number.
- Read the FDA warning letter, took the phrase both quoted passages turn on, and searched for it in the extracted visible text of both product pages. Zero occurrences on both, reported as an observation on one date rather than as a compliance conclusion.
- Fetched the warning letter URL and confirmed it returns a real page, with a nonsense warning-letter path on the same host in the same run returning a not-found response.
- Read the subject of the fifty-state sentence rather than the number in it, and stored no state list, with the pages-read census recorded on the row.
- Checked whether the oral dissolving tablet named in the letter appears as a priced product on either page read, and recorded that it does not.
- Printed the status, byte size and effective URL of every fetch, compared the effective path to the requested one, and ran a nonsense path against this host in the same run, which returned a not-found response.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. The full-text search also returned three unrelated recipients, so the entity name was matched exactly rather than counted. Untitled letters are published separately and were not searched.